Protecting First Responders January 9, 2016 • admin • Keeping our heroes safe from the dangers of chemical exposures. Related News Countervail’s principal investigator presents at 2009 NINDS CounterACT meeting in Washington, DC. Dr. Edson Albuquerque presents additional data on galantamine’s effectiveness in preserving survival and prevention of neural cell damage from nerve agent exposure. April 14, 2009 Countervail holds initial pre-IND meeting with Neurology Division of the FDA for guidance on development of a neuroprotectant against sub-lethal nerve agent exposure. October 5, 2012